Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study - Summary - MDSpire

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

  • By

  • Shungo Yamamoto

  • Akihiro Shiroshita

  • Yuki Kataoka

  • Hidehiro Someko

  • March 5, 2025

  • 0 min

Share

Objective:

To compare the effectiveness of ampicillin-sulbactam with ceftriaxone as initial treatment for community-acquired pneumonia (CAP) in older adults.

Key Findings:
  • Include adjusted odds ratios for a more comprehensive understanding.
Interpretation:

Strengthen the emphasis on the implications of higher mortality.

Limitations:
  • Mention potential confounding factors as a limitation.
Conclusion:

Suggest areas for further research.

Original Source(s)

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

  • by Shungo Yamamoto, Akihiro Shiroshita, Yuki Kataoka, Hidehiro Someko

  • March 5, 2025

Related Content

Match Day results show impact of federal immigration policy

Effectiveness of UV-C Technology for Environmental Decontamination of Clostridioides difficile in Hospital Settings: A Pre-Post Analysis

Framework Targets Hospital-Onset UTIs

The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.